Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MERCK & CO., INC.

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

New Analysis Shows Merck COVID-19 Pill Molnupiravir Less Effective Than Previously Reported

11/26/2021 | 10:06am EST


ę MT Newswires 2021
All news about MERCK & CO., INC.
01/14Pfizer Reportedly Seeks Japan Approval for COVID-19 Pill
MT
01/14Merck's COVID-19 Pill Molnupiravir Gets Emergency Approval in Indonesia
MT
01/12I-Mab Doses First Phase 2 Clinical Trial of Efineptakin Alfa, Keyrtruda Combination in ..
MT
01/12IMV Doses First Patient in Study for Lymphoma Treatment
DJ
01/11Aligos Therapeutics Shares Rise 6% on Merck Collaboration Agreement
DJ
01/11GLOBAL MARKETS LIVE : Airbus, Nokia, Pandora, Darktrace, Amazon...
01/11Today on Wall Street: All eyes on Powell
01/11Aligos Therapeutics, Merck Expand Collaboration in Nonalcoholic Steatohepatitis
MT
01/11Merck's KEYTRUDA (pembrolizumab) Showed Statistically Significant Improvement in Diseas..
AQ
01/11Gilead Announces Clinical Trial Collaborations With Merck to Evaluate Trodelvy in Combi..
AQ
More news
Analyst Recommendations on MERCK & CO., INC.
More recommendations
Financials (USD)
Sales 2021 48 687 M - -
Net income 2021 11 938 M - -
Net Debt 2021 17 019 M - -
P/E ratio 2021 17,4x
Yield 2021 3,21%
Capitalization 206 B 206 B -
EV / Sales 2021 4,57x
EV / Sales 2022 3,85x
Nbr of Employees 73 500
Free-Float -
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 81,38 $
Average target price 92,27 $
Spread / Average Target 13,4%
EPS Revisions
Managers and Directors
Robert M. Davis President, Chief Executive Officer & Director
Caroline A. Litchfield Chief Financial Officer & Executive Vice President
Kenneth C. Frazier Executive Chairman
Sandy Tremps Vice President-R&D IT CIO
Dave Williams Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
MERCK & CO., INC.6.18%205 561
JOHNSON & JOHNSON-1.89%441 855
ROCHE HOLDING AG-3.72%323 901
PFIZER, INC.-6.94%308 427
ABBVIE INC.0.35%240 202
ELI LILLY AND COMPANY-11.62%221 317